Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals.
The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted postprandially and contribute importantly to postprandial glucose tolerance. In this study, we assessed the individual and combined contributions of endogenous GIP and GLP-1 to the postprandial changes in glucose and glucoregulatory hormones using the novel GIP receptor antagonist GIP(3-30)NH2 and the well-established GLP-1 receptor antagonist exendin(9-39)NH2. During 4-h oral glucose tolerance tests (75 g) combined with an ad libitum meal test, 18 healthy men received on four separate days in randomized, double-blinded order intravenous infusions of A) GIP(3-30)NH2 (800 pmol/kg/min) plus exendin(9-39)NH2 (0–20 min: 1,000 pmol/kg/min; 20–240 min: 450 pmol/kg/min), B) GIP(3-30)NH2, C) exendin(9-39)NH2, and D) saline, respectively. Glucose excursions were significantly higher during A than during B, C, and D, while glucose excursions during B were higher than during C and D. Insulin secretion (assessed by C-peptide/glucose ratio) was reduced by 37 ± 16% (A), 30 ± 17% (B), and 8.6 ± 16% (C) compared with D (mean ± SD). A and C resulted in higher glucagon levels and faster gastric emptying. In conclusion, endogenous GIP affects postprandial plasma glucose excursions and insulin secretion more than endogenous GLP-1, but the hormones contribute additively to postprandial glucose regulation in healthy individuals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glucose-dependent insulinotropic polypeptide is the primary incretin hormone responsible for mealstimulated insulin secretion in healthy individuals.7”
From Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (2022) · cites this paper as [7]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604 · cited 1×
“A lack of effect of exendin(9-39) NH2 on food consumption has been reported in previous studies (42,43) and could be due to simultaneously increased levels of peptide YY (10,30,34,37), stimulating satiety (44).”
BackgroundReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 8×
“Study Design Each participant served as his own control and attended four 75-g OGTTs on four separate study days in a randomized order with infusion of GIP(3-30)NH2 (260 min at a rate of 800 pmol/kg/min), exendin(9-39)NH2 (20 min at 1,000 pmol/kg/min followed by 240 min at 450 pmol/ kg/min), GIP(3-30)NH2 and exendin(9…”
BackgroundMethodInfluentialTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 8×
“Study Design Each participant served as his own control and attended four 75-g OGTTs on four separate study days in a randomized order with infusion of GIP(3-30)NH2 (260 min at a rate of 800 pmol/kg/min), exendin(9-39)NH2 (20 min at 1,000 pmol/kg/min followed by 240 min at 450 pmol/ kg/min), GIP(3-30)NH2 and exendin(9…”
BackgroundMethodInfluentialSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Self-citationSteinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578 · cited 2×
“5A and Table 2]), may contribute to explain the lack of effect of exendin(9-39)NH2 on typical GLP-1 effects such as food intake and insulin secretion as previously described (31,43,48).”
Background
Research works printed but not linked: 2
- Pacini, 2005, The insulinogenic index is a valid marker of beta cell function in different metabolic categories, Diabetes, 54, A370
- Bergmann, 2017, The effects of GIP/GLP-1 receptor co-activation on appetite and food intake in overweight/obese subjects, Diabetologia, 60, S5
Cited by
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Nauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
The carbohydrate-insulin model: A physiological perspective on the obesity pandemic
Ludwig, D. S., Aronne, L. J., Astrup, A., de Cabo, R., Cantley, L. C., Friedman, M. I., Heymsfield, S. B., Johnson, J. D., King, J. C., Krauss, R. M., et al. (2021) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqab270 · Cited by 292
Min, T., & Bain, S. C. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00981-0 · Cited by 285
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146353 · Cited by 256
The incretin system in healthy humans: The role of GIP and GLP-1
Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248
Self-citationEffects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
“Although GIP is physiologically important for incretin action in animals and humans 166 , the insulin stimulatory actions of GIP are diminished in the setting of experimental and clinical diabetes mellitus 22 .”
The expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
Self-citationGIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Holst, J. J., & Rosenkilde, M. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa327 · Cited by 207
Self-citationThe metabolic impact of small intestinal nutrient sensing
Duca, F. A., Waise, T. M. Z., Peppler, W. T., & Lam, T. K. T. (2021) · Nature Communications · doi:10.1038/s41467-021-21235-y · Cited by 205
Metabolic messengers: glucagon-like peptide 1
Gribble, F. M., & Reimann, F. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00327-x · Cited by 199
Negi, C. K., Babica, P., Bajard, L., Bienertova-Vasku, J., & Tarantino, G. (2022) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 190
Incretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
Mayendraraj, A., Rosenkilde, M. M., & Gasbjerg, L. S. (2022) · Peptides · doi:10.1016/j.peptides.2022.170749 · Cited by 154
Self-citationCampbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149
From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
Holst, J. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00260 · Cited by 147
Self-citationLi, Y., Qin, C. X., Dong, L., Zhang, X., Wu, Z., Liu, L., Yang, J., & Liu, L. (2022) · Food & Function · doi:10.1039/d2fo01746f · Cited by 156
Regmi, A., Aihara, E., Christe, M. E., Varga, G., Beyer, T. P., Ruan, X., Beebe, E., O’Farrell, L. S., Bellinger, M. A., Austin, A. K., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.010 · Cited by 130
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133
GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
El, K., Gray, S. M., Capozzi, M. E., Knuth, E. R., Jin, E., Svendsen, B., Clifford, A., Brown, J. L., Encisco, S. E., Chazotte, B. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf1948 · Cited by 132
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“https://doi.org/10.1038/s42255-024-01113-9 insulin secretion observed when glucose (and other nutrients) is taken in orally as compared to intravenous administration 29 .”
InfluentialSelf-citationThe Role of Incretins on Insulin Function and Glucose Homeostasis
Holst, J. J., Gasbjerg, L. S., & Rosenkilde, M. M. (2021) · Endocrinology · doi:10.1210/endocr/bqab065 · Cited by 124
Self-citationFisman, E. Z., & Tenenbaum, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01412-5 · Cited by 124
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
De Block, C., Bailey, C., Wysham, C., Hemmingway, A., Allen, S. E., & Peleshok, J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14831 · Cited by 121
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121
Self-citationIncretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
Boer, G. A., & Holst, J. J. (2020) · Biology · doi:10.3390/biology9120473 · Cited by 153
Self-citationAdverse Events Related to Tirzepatide
Mishra, R., Raj, R., Elshimy, G., Zapata, I., Kannan, L., Majety, P., Edem, D., & Correa, R. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad016 · Cited by 110
The role of GIP in α-cells and glucagon secretion
El, K., & Campbell, J. E. (2020) · Peptides · doi:10.1016/j.peptides.2019.170213 · Cited by 96
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 112
Self-citationNew Insights into Beta-Cell GLP-1 Receptor and cAMP Signaling
Tomas, A., Jones, B., & Leech, C. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.08.009 · Cited by 86
Leveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 83
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
Self-citationVarney, M. J., & Benovic, J. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001015 · Cited by 89
The incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77
Self-citationActions of glucagon‐like peptide‐1 receptor ligands in the gut
Holst, J. J., Andersen, D. B., & Grunddal, K. V. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15611 · Cited by 73
Self-citationTheilade, S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14270 · Cited by 82
Self-citationGIP and GLP-1 receptor antagonism during a meal in healthy individuals
Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz175 · Cited by 68
Self-citationGut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
GIP and GLP-1: stepsiblings rather than monozygotic twins within the incretin family
Nauck, M. A., & Meier, J. J. (2019) · Diabetes · doi:10.2337/dbi19-0005 · Cited by 65
Bergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0578 · Cited by 62
Self-citationHuber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62
“The incretin effect of GLP-1 and GIP has been demonstrated in animal studies, and now, with the help of antagonists for both receptors, the importance of incretin hormones for the maintenance of NGT has been demonstrated [31,100 – 102].”
BackgroundSelf-citationThe role of endogenous GIP and GLP-1 in postprandial bone homeostasis
Helsted, M. M., Gasbjerg, L. S., Lanng, A. R., Bergmann, N. C., Stensen, S., Hartmann, B., Christensen, M., Holst, J. J., Vilsbøll, T., ROSENKILDE, M. M., et al. (2020) · Bone · doi:10.1016/j.bone.2020.115553 · Cited by 64
Self-citationWeight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“The initial attention in the clinical space for GLP-1 was related to the glucose-dependent insulin secretion effect, often referred to as the incretin effect [85].”
Gabe, M. B. N., van der Velden, W. J. C., Gadgaard, S., Smit, F. X., Hartmann, B., Bräuner‐Osborne, H., & Rosenkilde, M. M. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13289 · Cited by 55
Self-citationHolst, J. J., Albrechtsen, N. J. W., Rosenkilde, M. M., & Deacon, C. F. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180013 · Cited by 54
Self-citationGIP analogues and the treatment of obesity-diabetes
Bailey, C. J. (2019) · Peptides · doi:10.1016/j.peptides.2019.170202 · Cited by 58
Samms, R. J., Sloop, K. W., Gribble, F. M., Reimann, F., & Adriaenssens, A. E. (2021) · Diabetes · doi:10.2337/dbi21-0002 · Cited by 49
“To the contrary, acute infusion of supraphysiological levels of GIP has no effect on body weight, food intake, or caloric expenditure in adult humans (13).”
BackgroundZaffina, I., Pelle, M. C., Armentaro, G., Giofrè, F., Cassano, V., Sciacqua, A., & Arturi, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1095753 · Cited by 56
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
HINDSØ, M. G., Hedbäck, N., Svane, M. S., Møller, A., Martinussen, C., Jørgensen, N. B., Dirksen, C., Gasbjerg, L. S., Kristiansen, V. B., Hartmann, B., et al. (2022) · Diabetes · doi:10.2337/db22-0568 · Cited by 49
Self-citationPsaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 51
Gasbjerg, L. S., Rosenkilde, M. M., Meier, J. J., Holst, J. J., & Knop, F. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15216 · Cited by 41
Self-citationGIP’s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3–30)NH2
Gasbjerg, L. S., Hartmann, B., Christensen, M. B., Lanng, A. R., Vilsbøll, T., Jørgensen, N. R., Holst, J. J., Rosenkilde, M. M., & Knop, F. K. (2020) · Bone · doi:10.1016/j.bone.2019.115079 · Cited by 40
Self-citationGLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells
Shilleh, A. H., Viloria, K., Broichhagen, J., Campbell, J. E., & Hodson, D. J. (2024) · Peptides · doi:10.1016/j.peptides.2024.171179 · Cited by 39
“Thus, delta cell-regulation of alpha cells could constitute a potentially important route for the glucagonostatic effects of GLP1RA.”
Kelly, A. T., Sheikh, S., Stefanovski, D., Peleckis, A. J., Nyirjesy, S. C., Eiel, J. N., Sidhaye, A. R., Localio, R., Gallop, R., León, D. D. D., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab365 · Cited by 39
Gabe, M. B. N., van der Velden, W. J. C., Smit, F. X., Gasbjerg, L. S., & Rosenkilde, M. M. (2020) · Peptides · doi:10.1016/j.peptides.2019.170224 · Cited by 37
Self-citationGIP’s involvement in the pathophysiology of type 2 diabetes
Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170178 · Cited by 35
Self-citationBaldassano, S., Gasbjerg, L. S., Kizilkaya, H. S., ROSENKILDE, M. M., Holst, J. J., & Hartmann, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00492 · Cited by 34
Self-citationRecent advances of GIP and future horizons
Holst, J. J., & Rosenkilde, M. M. (2020) · Peptides · doi:10.1016/j.peptides.2019.170230 · Cited by 33
Self-citationMetabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors
Deacon, C. F. (2020) · Peptides · doi:10.1016/j.peptides.2019.170196 · Cited by 31
Gasbjerg, L. S., Rasmussen, R. S., Dragan, A., Lindquist, P., Melchiorsen, J. U., Stępniewski, T. M., Schiellerup, S. P., Tordrup, E. K., Gadgaard, S., Kizilkaya, H. S., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16478 · Cited by 34
Self-citationIrwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides · doi:10.1016/j.peptides.2019.170203 · Cited by 27
Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome
Αλεξιάδου, Κ., & Tan, T. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01309-9 · Cited by 27
Exendin(9‐39) NH 2 : Recommendations for clinical use based on a systematic literature review
Gasbjerg, L. S., Bari, E. J., Christensen, M., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14507 · Cited by 29
Self-citationGrespan, E., Giorgino, T., Natali, A., Ferrannini, E., & Mari, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154415 · Cited by 27
Walker, E. G., Lo, K., Pahl, M. C., Shin, H. S., Lang, C., Wohlers, M. W., Poppitt, S. D., Sutton, K. H., & Ingram, J. R. (2022) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqab418 · Cited by 26
Christensen, M., Lund, A., Jørgensen, N. R., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa097 · Cited by 25
Self-citationGasbjerg, L. S., Bari, E. J., Stensen, S., Hoe, B., Lanng, A. R., Mathiesen, D. S., Christensen, M. B., Hartmann, B., Holst, J. J., Rosenkilde, M. M., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14186 · Cited by 24
Self-citationCombination gut hormones: prospects and questions for the future of obesity and diabetes therapy
Khoo, B. C. E., & Tan, T. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0119 · Cited by 23
Holst, J. J. (2021) · Diabetes · doi:10.2337/dbi21-0026 · Cited by 23
“Our current hypothesis is that the processing of proglucagon in the pancreas is not 100% specific and that a minor fraction of proglucagon actually is processed to GLP-1(7-36)-amide (in humans, amidation of GLP-1 seems to be rather extensive) (22).”
BackgroundResultInfluentialSelf-citationBulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 31
GIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology
ROSENKILDE, M. M., Lindquist, P., Kizilkaya, H. S., & Gasbjerg, L. S. (2024) · Peptides · doi:10.1016/j.peptides.2024.171212 · Cited by 22
Self-citationPhysiological Appetite Regulation and Bariatric Surgery
Ramasamy, I. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051347 · Cited by 27
Glucagon‐like peptide‐1: Are its roles as endogenous hormone and therapeutic wizard congruent?
Holst, J. J. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13433 · Cited by 25
Self-citationBandt, D. D., Rives‐Lange, C., Frigout, Y., Bergerot, D., Blanchard, A., Gall, M. L., Lacorte, J., Chevallier, J., Czernichow, S., Poghosyan, T., et al. (2022) · Obesity Surgery · doi:10.1007/s11695-021-05837-5 · Cited by 20
Smith, K., Taylor, G., Walker, M., Brunsgaard, L. H., Davies, K. A. B., Stevenson, E., & West, D. J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad069 · Cited by 23
RISING STARS: Endocrine regulation of metabolic homeostasis via the intestine and gut microbiome
Meyer, R. K., & Duca, F. A. (2023) · Journal of Endocrinology · doi:10.1530/joe-23-0019 · Cited by 28
Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists
Myerson, M. L., & Paparodis, R. D. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2487 · Cited by 20
Ruze, R., Xu, Q., Liu, G., Li, Y., Chen, W., Cheng, Z., Xiong, Y., Liu, S., Zhang, G., Hu, S., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00126.2021 · Cited by 20
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Self-citationYu, Y., Hu, G., Yin, S., Yang, X., Zhou, M., & Jian, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.990182 · Cited by 17
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad285 · Cited by 18
Association of a glucagon‐like peptide‐1 receptor gene variant with glucose response to a mixed meal
Mashayekhi, M., Wilson, J. R., Kerman, S. R. J., Nian, H., Yu, C., Shuey, M. M., Luther, J. M., & Brown, N. J. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14216 · Cited by 18
Petrov, M. S. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1931118 · Cited by 18
Fahim, S. A., Attia, Y. M., Messiha, A. A., Nabawy, A. Y., Refaat, F., & El-Maadawy, W. H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118731 · Cited by 22
West, J. A., Ghosh, S. S., Parkes, D. G., Tsakmaki, A., Grønlund, R. V., Pedersen, P. J., MAGGS, D. G., Rajagopalan, H., & Bewick, G. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249239 · Cited by 19
Åhrén, B. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13836 · Cited by 17
Chu, L., Terasaki, M., Mattsson, C. L., Teinturier, R., Charbord, J., Dirice, E., Liu, K., Miskelly, M. G., Zhou, Q., Wierup, N., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.08.001 · Cited by 16
Douros, J. D., Flak, J. N., & Knerr, P. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1530985 · Cited by 18
GIP(3-30)NH2 – a tool for the study of GIP physiology
Lynggaard, M. B., Gasbjerg, L. S., Christensen, M., & Knop, F. K. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.011 · Cited by 17
Self-citationSmith, K., Taylor, G., Allerton, D. M., Brunsgaard, L. H., Davies, K. A. B., Stevenson, E., & West, D. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.696977 · Cited by 18
Tirzepatide: a new low for bodyweight and blood glucose
Bailey, C. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00217-5 · Cited by 18
Nowak, M., Nowak, W., & Grzeszczak, W. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2022.0029 · Cited by 27
Metadata
- Authors
- Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., Holst, J. J., Rosenkilde, M. M., & Knop, F. K.
- Affiliations
- University of Copenhagen (DK)
- Gentofte Hospital (DK)
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Corresponding author
- Knop, Filip K.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2019-01-09
- Volume
- 68
- Issue
- 5
- Pages
- 906-917
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2909748938
- Semantic Scholar
- 8d259751958bd756f4a81231f9791af24dbcf3b4
- Cited by
- 193
- References
- 52
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 34 · 2023: 21 · 2022: 25 · 2021: 26 · 2020: 18 · 2019: 24
- FWCI
- 18.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- European Foundation for the Study of Diabetes
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, incretins, postprandial glucose regulation, GIP receptor antagonist, exendin-9-39, insulin secretion, glucagon, gastric emptying, oral glucose tolerance test, healthy men
- MeSH terms
- Insulin Secretion, Adult, Blood Glucose, Gastric Emptying, Gastric Inhibitory Polypeptide, Glucagon, Glucose, Glucose Tolerance Test, Humans, Infusions, Intravenous, Male, Peptide Fragments, Receptors, Gastrointestinal Hormone, Postprandial Period, Glucagon-Like Peptide 1, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.